Areas of Research
At utR Biotech, our mission is to revolutionize the treatment of Type 1 Diabetes (T1D) and its associated complications. Our research spans several critical areas, including the development of innovative therapies that integrate insulin and specific proteins, which are poised to address key challenges in diabetes management and related diseases.
Diabetes and Neuropathy
One of our primary research areas is the prevention of diabetic complications, particularly neuropathy, which affects nearly 50% of individuals with T1D. Our research aims to demonstrate how integrating specific proteins with insulin can protect nerve cells by restoring calcium ion balance and preventing cellular dysfunctions that lead to nerve damage. This novel approach seeks to reduce the progression of neuropathy, offering patients a more effective way to manage this debilitating complication.
Alzheimer’s Disease and Memory Loss
We are investigating the link between T1D and the onset of Alzheimer’s disease. Our studies focus on how protein supplementation, when combined with insulin, may delay or prevent memory deficits and cognitive decline by reducing the neuropathic effects triggered by long-term diabetes. Our work includes animal models that simulate Alzheimer’s progression in diabetic subjects, providing critical insights into how insulin and protein therapies may protect against these neurological conditions.
Cardiovascular Disease
Cardiovascular complications are a leading cause of mortality among diabetic patients. Our research focuses on how insulin and specific protein therapies can reduce the risk of cardiovascular diseases like atherosclerosis and diabetic cardiomyopathy. By studying calcium transport mechanisms in diabetic heart cells, we aim to develop therapies that help restore proper heart function, thereby mitigating the cardiovascular risks associated with diabetes.
Cancer and Mitochondrial Dysfunction
Individuals with T1D are at an increased risk for certain types of cancers. Our pioneering research examines how specific proteins may reduce cancer risk in diabetic patients. We are developing animal models to study the relationship between proteins, mitochondrial dysfunction, and cancer cell development. Our focus on mitochondrial health is key, as it plays a significant role in both cancer progression and diabetes.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Our research extends into metabolic diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD), which disproportionately affects individuals with diabetes. We are investigating how protein and insulin therapies can prevent the progression of NAFLD to more severe liver conditions, such as Non-Alcoholic Steatohepatitis (NASH). Our goal is to offer new therapeutic solutions that improve liver health in diabetic patients.
Advanced Bioanalytics and Electrochemistry
We are at the forefront of integrating Artificial Intelligence (AI) and electrochemical technologies to revolutionize diabetes treatments. By utilizing advanced datasets, we map genetic, immune, and biological functions to explore novel therapies. Our research focuses on non-invasive, real-time monitoring of insulin-protein interactions with living cells. This includes quantifying calcium ion concentrations and analyzing cell membrane potentials to evaluate the effectiveness of our therapies. These cutting-edge techniques allow us to optimize our treatment formulations while advancing our understanding of cellular responses.
WoundRay® Wound Healing Solution
WoundRay® is a cutting-edge diabetic wound healing solution that combines the power of infrared (IR) light therapy with an advanced topical healing cream to promote faster and more effective wound recovery. Designed specifically for patients suffering from difficult-to-heal wounds caused by diabetes, WoundRay® harnesses the regenerative properties of IR light to improve blood circulation, stimulate cellular repair, and reduce inflammation in affected areas. The topical cream is enriched with a blend of bioactive compounds that accelerate tissue regeneration, moisturize the skin, and prevent infection, creating an optimal environment for healing. This dual-action approach addresses the unique challenges of diabetic wounds, which are often slow to heal due to impaired circulation and immune response. WoundRay® offers a breakthrough treatment option that helps reduce healing time and lowers the risk of complications, such as infections or amputations, enhancing the quality of life for diabetic patients.
Product Targets
At utR Biotech, we are focused on developing breakthrough therapies for both human and veterinary insulin markets. Through innovative formulations, streamlined manufacturing, and efficient distribution, we are committed to meeting the diverse needs of patients worldwide while maintaining the highest standards of safety and efficacy.
Human Insulin Products
Our core product line is centered around developing advanced insulin formulations that integrate specific proteins with insulin to improve therapeutic outcomes for patients with Type 1 diabetes. These formulations are designed not only to regulate blood glucose levels but also to prevent long-term complications such as neuropathy, cardiovascular disease, and cognitive decline. Our goal is to significantly enhance the quality of life for millions of people who rely on insulin.
Veterinary Insulin Products
We also recognize the growing demand for diabetes treatments in animals. Our veterinary insulin products are developed with the same scientific rigor as our human formulations, offering precise glucose control for pets and livestock with diabetes. By extending our expertise to the veterinary space, we aim to improve health outcomes for animals, providing veterinarians with reliable and accessible treatment options.
Extended Shelf-Life Formularies
A key innovation at utR Biotech is our development of uTRInsulin LL™, an insulin formulation with a drastically extended shelf life. These products remain stable for up to 24 months, making them ideal for use in regions with limited refrigeration infrastructure. By extending insulin’s shelf life, we aim to reduce waste, lower costs, and increase global access to essential insulin therapies.
Manufacturing & Distribution
At utR Biotech, we are committed to optimizing our manufacturing processes to enhance production efficiency and reduce costs, ensuring that we can offer competitively priced insulin formulations without compromising on quality.
Manufacturing Processes and Streamlining
utR Biotech is committed to streamlining manufacturing processes to enhance production efficiency and reduce costs. We employ state-of-the-art expression systems for high-yield production of recombinant insulin and protein. By optimizing enzymatic cleavage and purification processes, we significantly lower production time and expenses, enabling us to offer competitively priced insulin formulations without compromising quality.
Packaging and Distribution Technology
Our innovative packaging solutions are designed to facilitate the safe, effective, and convenient distribution of our insulin products globally. We use advanced packaging techniques to protect the integrity of uTRInsulin LL® products during transit and storage. Our focus is on minimizing temperature excursions and ensuring product stability in diverse environments. We also include user-friendly packaging for easy resuspension and administration, further enhancing the patient experience.